Drug Sponsors

Biogen Idec acquires full rights of Tysabri from Elan

Wednesday, February 6, 2013 11:41 AM

Biogen Idec, an independent biotechnology company, has agreed to purchase biotech Elan’s full strategic, commercial and decision-making rights to Tysabri.

More... »

Gilead Sciences acquires YM BioSciences

Wednesday, February 6, 2013 11:12 AM

The Supreme Court of Nova Scotia has issued a final order approving the previously announced plan involving YM BioSciences, Gilead Sciences and Nova Scotia Limited, a wholly-owned subsidiary of Gilead. Nova Scotia Limited will acquire all of the issued and outstanding common shares of YM BioSciences for cash consideration of $2.95 per common share.

More... »

Idenix Pharmaceuticals cancels IDX184 and IDX19368 programs for HCV

Wednesday, February 6, 2013 09:45 AM

Idenix Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the company had previously filed an IND but had not initiated patient dosing.

More... »

Elan sells remaining stake in Alkermes

Friday, February 1, 2013 01:43 PM

Following the close of trading today, Elan’s wholly-owned subsidiary, Elan Science Three, agreed to sell, on customary terms, all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company pursuant to Rule 144 under the U.S. Securities Act of 1933. The sale is expected to close on February 6, 2013.

More... »

Ocular Therapeutix closes $23.8M Series D extension

Wednesday, January 30, 2013 10:39 AM

Ocular Therapeutix, a privately held company based in Bedford, Mass.,recently closed a Series D extension round of financing totaling $23.8 million.

More... »

Boston Scientific expands restructuring program

Wednesday, January 30, 2013 10:11 AM

Boston Scientific, a medical device company based in Natick, Mass., has announced an expansion of its 2011 restructuring program intended to build on the progress made under that program to strengthen its operational effectiveness and efficiencies and support new growth investments, which is expected to increase shareholder value. 

More... »

Celsion, Zhejiang Hisun enter into tech development agreement for ThermoDox

Monday, January 28, 2013 10:24 AM

Celsion, an oncology drug development company, and Zhejiang Hisun Pharmaceutical, a Chinese pharmaceutical company, have entered into a technology development agreement for ThermoDox for the Greater China territory. 

More... »

Salk Institute awarded $42M from Helmsley Charitable Trust

Monday, January 28, 2013 09:55 AM

The Salk Institute for Biological Studies, a San Diego-based institute focused both on discovery and on mentoring future generations of researchers, has received a $42 million gift from The Leona M. and Harry B. Helmsley Charitable Trust to establish the Helmsley Center for Genomic Medicine (HCGM).

More... »

DelMar Inc. acquires shares of DelMar Ltd.

Friday, January 25, 2013 01:43 PM

DelMar Pharmaceuticals, Inc., a Canadian pharmaceutical company that develops drug candidates targeting orphan cancer indications, has completed the acquisition of all of the outstanding shares of DelMar Pharmaceuticals Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer. 

More... »

Domain grants Prexton exclusive license and development of mGluR4 PAMs for Parkinson’s

Friday, January 25, 2013 11:01 AM

Domain Therapeutics, a French biopharmaceutical company, has granted Switzerland–based Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease.

More... »